Enlivex Therapeutics R&D Company
"Cell Immunotheraphy for Autoimmune and Inflammatory Conditions."
Enlivex Therapeutics R&D, a clinical-stage company focused on specialized cell immunotherapy, develops and commercializes an allogeneic drug pipeline for rebalancing immune hyper-responses.
The company’s Allocetra aims to effectively treat numerous acute conditions by using the body’s native mechanisms to restore rather than suppress immune balance. Enlivex aims to reshape the way immune, autoimmune, and inflammatory conditions are thought of and treated.
In March 2019, the company announced the completion of its merger with Tel Aviv-headquartered Bioblast Pharma, a stock market-listed clinical-stage company developing treatments for rare genetic diseases. Following the reverse merger, Enlivex became a subsidiary of Bioblast, which was renamed Enlivex Therapeutics.
Combating Coronavirus Pandemic:
Enlivex Therapeutics R&D's solution helps address the Coronavirus Pandemic.
Enlivex Therapeutics R&D, a clinical-stage company focused on specialized cell immunotherapy, develops and commercializes an allogeneic drug pipeline for rebalancing immune hyper-responses.
The company’s Allocetra aims to effectively treat numerous acute conditions by using the body’s native mechanisms to restore rather than suppress immune balance. Enlivex aims to reshape the way immune, autoimmune, and inflammatory conditions are thought of and treated.
In March 2019, the company announced the completion of its merger with Tel Aviv-headquartered Bioblast Pharma, a stock market-listed clinical-stage company developing treatments for rare genetic diseases. Following the reverse merger, Enlivex became a subsidiary of Bioblast, which was renamed Enlivex Therapeutics.
Combating Coronavirus Pandemic:
Enlivex Therapeutics R&D's solution helps address the Coronavirus Pandemic.
Technology:
COVID Treatments
Industry:
Vaccine Development
Headquarters:
Israel
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership